Author Of 1 Presentation
IGM-ENRICHED IMMUNOGLOBULIN (3 DAYS VS. 5 DAYS) AS ADJUVANT TREATMENT FOR SERIOUS INFECTIOUS DISEASE IN PEDIATRIC INTENSIVE CARE UNIT: RETROSPECTIVE, SINGLE-CENTER EXPERIENCE (PIGMENT STUDY)
Abstract
Background
Although there are studies in different age groups regarding the infusion of polyclonal IgM-enriched intravenous immunoglobin (Pentaglobin) in the treatment of sepsis, data on use in pediatric intensive care units are limited.
Objectives
The aim of this study was to evaluate clinical features and prognosis of children receiving Pentaglobin in the pediatric infectious disease unit due to serious infections.
Methods
We evaluated medical records of 254 children (aged between 1-216 months), receiving Pentaglobin infusion (104 children for 3 days,150 children for 5 days) in addition to standard treatment between 2010-2017.
Results
The mortality rate was lower in patients receiving Pentaglobin for 5-days comparing the patients receiving for 3-days (p<0.05). We observed a decreased mortality rate in 5-days group in children with sepsis, septic shock, and multi-organ failure groups, whereas the statistical significance has been only observed in septic shock group(p<0.05). According to the microbiological results, decreased mortality rate has been observed in all patients receiving 5-days treatment, while the statistical difference has been only observed for the infections due to Gram-negative pathogens(p<0.05). Statistical significance has been observed among children aged between 1-24 months between 5-days and 3-days group (p<0.05).
Conclusion
Polyclonal IgM-enriched immunoglobulin for 5-days as an adjuvant treatment for the serious infectious disease in the pediatric intensive care unit, showed a significant reduction for mortality in septic shock cases. The effect was shown to be more pronounced for gram-negative infections and for the 1-24-months age group. Prospective randomized controlled trials needed to support these results.